PLANO, Texas, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced participation at the Wells Fargo 2024 Healthcare Conference, to be held Sept. 4 – 6, 2024, in Boston. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present on Wednesday, Sept. 4, at 2:15 pm EDT.
A live webcast of the presentation will be accessible under “News & Events” on the Investor Relations section of the Integer website at investor.integer.net.
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: Andrew Senn This email address is being protected from spambots. You need JavaScript enabled to view it. 763.951.8312 | Media Relations: Kelly Butler This email address is being protected from spambots. You need JavaScript enabled to view it. 469.731.6617 |
| Last Trade: | US$116.98 |
| Daily Change: | 0.77 0.66 |
| Daily Volume: | 806,507 |
| Market Cap: | US$3.920B |
March 18, 2025 March 12, 2025 February 20, 2025 February 18, 2025 February 03, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
